Drugs / ALK Alutard Birch
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable1 trial | ||||||
| — | NCT03375775 | May 2017 → Jan 2022 | allergic rhinitis, asthma, conjunctivitis | Karolinska Institutet | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 2/3 | NCT02975479 Comparator | May 2016 → Jun 2022 | seasonal allergic rhinitis | Karolinska Institutet | Completed | No outcome recorded |
| Phase 2/3 | NCT02679105 Comparator | May 2015 → Oct 2016 | allergic rhinitis | Karolinska Institutet | Completed | No outcome recorded |
| Phase 2/3 | NCT02423707 Comparator | Aug 2010 → Nov 2015 | allergic rhinitis | Karolinska Institutet | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALK Alutard birch | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03375775 ↗ |
| Known as | ALK-alutard SQ Betula verrucosa | “The substance used for the three intralymphatic injections is ALK-alutard SQ Betula verrucosa® and ALK-alutard SQ 5-grasses ® under ATC-code V01AA, V04CL and V07AB which is a...” NCT02423707 ↗ |
| Route | Other | “intralymphatic injections” NCT02423707 ↗ |